Psychotic Disorder Treatment Market Sales Surge with Increasing Consumer Focus,
Posted by Arslan on June 11th, 2019
Burgeoning prevalence of lifestyle-related mental conditions coupled with the growing number of bipolar disorders has been necessitating the development of effective-psychotic disorder treatment. Surging number of patients suffering from bipolar disorders, depressive disorders, schizophrenia and other mental disorders are accelerating the traction for psychotic disorder treatment.
Growing awareness about the vital role of early prevention of mental disorders in minimizing the damage caused by these conditions has the potential to drive the psychotic disorder treatment market in the coming years. Moreover, easy availability of psychotic drugs in hospital pharmacies, drug stores, commerce, and retail pharmacies are fueling their sales. These factors are driving growth in the Psychotic Disorder Treatment Market.
The emergence of atypical antipsychotic drugs in the psychotic disorder treatment market has transformed the scenario of mental disorders. Consequently, individuals with mental disorders no longer needed to be physically bound and could be managed with drug treatment and medication.
The global psychotic disorder treatment market is anticipated to be driven by growing cases of mental disturbances, such as depression, trauma, and stress. Furthermore, growing inventions of the molecules and increasing healthcare and medical investment in the R&D of metal disorders are favoring growth of psychotic disorder market.
The World Health Organization (WHO) estimates that more than 21 million people worldwide suffered from schizophrenia in 2016, and stated that one in two people with this condition don’t receive appropriate psychotic disorder treatment. This is further creating an opportunity for the stakeholders in the psychotic disorder treatment market to develop cost-effective medications to extend their reach to a wider target base.
Treatment strategies for managing patients with psychotic disorders are multi-faceted. Over the past couple of decades, doctors have been exploring the effectiveness of various therapies for psychotic disorders, particularly for schizophrenia. While strategies on medications have had substantial impacts on treating the symptoms in patients, there lurks significant risk of relapse, especially in case of acute psychotic episodes. In recent times, this has been driving considerable deal of research in nonpharmacologic treatment approaches opening a new avenue in the Global Psychotic Disorder Treatment Market. These approaches have gained significance of late as they help in boosting medication compliance in patients.
A successful psychotherapy appears promising for managing the patients and may help them adapt to real world faster. Thus, recent studies on cognitive therapy as an adjunct to medication for patients with psychotic disorders augur well for the market expansion. Psychoeducation is another area that merits attention among researchers. This is especially crucial for treating the recurrent episodes of hallucinations and delusions characterized in disorders that may persist life-long. Recent studies seek to shed light on cognitive models of psychotherapy in this regard. Clinicians have been harping on multilevel approach to assess the effectiveness of patient-directed psychoeducation. This is expected to open a new paradigm in the evolution of the market.
Psychotic disorders psychotic disorder treatment are mental disorders in which a person’s personality is affected severely due to brain damage. When a psychotic episode happens, a person becomes uncertain about reality and usually experiences delusions, hallucinations, off-the-wall behavior, incoherency and chaotic speech. Psychotic disorders generally shows two main symptoms that are hallucinations and delusions. Hallucinations are wrong perceptions, such as seeing, hearing or feeling something that is not present. Delusions are wrong beliefs, involving real-life conditions that could not be true, such as having a disease. Depending on the causes, psychotic disorder can come slowly or quickly. Psychosis is not a permanent state rather it can be cured. The exact cause of psychotic disorder is unclear but psychosis is usually results from brain abnormalities. Psychotic disorder can also be associated with dementia, stroke, schizophrenia, brain tumors, bipolar disorders, heavy use and adverse effect to alcohol or drugs. Medication plays an important role in the treatment of psychotic disorder. Highly-effective treatments are available to treat psychotic disorder which includes antipsychotic medication, cognitive behavioral therapy, supportive psychotherapy and case management.
Psychotic Disorder Treatment Market: Drivers and Restraints
The global psychotic disorder treatment market is anticipated to register a significant CAGR over a forecast period. The increasing research and development activities for the new drugs and new combinations of drugs to minimize the adverse effects of the antipsychotics drugs and increase safety and efficacy of the drug is anticipated to boost the demand for the psychotic disorder drugs and drives the global psychotic disorder treatment market. Increasing the number of prevalence of severe psychotic disorder is likely to fuel the growth of global psychotic disorder treatment market. The rising in the awareness among people is also anticipated to drives the global psychotic disorder treatment market.
However, the possible side effects of the antipsychotics drugs may hamper the demand for the psychotic disorder treatment and restrain the growth of the global psychotic disorder treatment market. Lack of specific drugs and methods is a significant challenge to ensure the treatment is another factor that hinder the demand for the psychotic disorder treatment and restrain the growth of global psychotic disorder treatment market.
Psychotic Disorder Treatment Market: Regional Outlook
On the basis of regional presence, the global psychotic disorder treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East & Africa. Currently, North America is contributing the leading shares to the global psychotic disorder treatment market in terms of value due to increase in the number of prevalence of severe psychotic disorder among people and is anticipated to register a significant CAGR over a forecast period. APEJ is also contributing moderate shares to the market and is expected to show a robust growth to the global psychotic disorder treatment market. Europe is also most lucrative market for the psychotic disorder treatment market. MEA is at a nascent stage to the global psychotic disorder treatment market and anticipated to register a decent growth to the market over a forecast period. Overall, the global psychotic disorder treatment market is expected to show significant growth over a forecast period.
Psychotic Disorder Treatment Market: Key Players
Some of the major market players in psychotic disorder treatment market globally includes: Teva Pharmaceutical Industries Ltd, Sanofi S.A., Allergan, Plc, Pfizer Inc, Novartis International AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. and others. These companies are highly focused on the development of advanced Psychotic disorder treatment devices further contributing to the growth of psychotic disorder treatment globally.
Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=568
Like it? Share it!
About the AuthorArslan
Joined: December 18th, 2017
Articles Posted: 13,297
More by this author